AMRX Q2 2020 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$465M+14.8% YoY

Gross Profit

$144M31.0% margin

Operating Income

$11M2.3% margin

Net Income

-$12M-2.6% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

$179M

Free Cash Flow

$171M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$4.1B

Total Liabilities

$3.7B

Stockholders' Equity

$306M

Cash & Equivalents

$266M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$465M	$405M	+14.8%
Gross Profit	$144M	$105M	+37.0%
Operating Income	$11M	-$19M	+156.8%
Net Income	-$12M	-$17M	+29.0%

Revenue Segments

Generics Segment

$307M66%

Amneal Specialty Pharma Segment

$94M20%

Av K A R E Segment

$64M14%